Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).

PubWeight™: 1.02‹?› | Rank: Top 15%

🔗 View Article (PMC 2363865)

Published in Br J Cancer on April 20, 2001


A Hauschild1, C Garbe, W Stolz, U Ellwanger, S Seiter, R Dummer, S Ugurel, G Sebastian, D Nashan, R Linse, W Achtelik, P Mohr, R Kaufmann, M Fey, J Ulrich, W Tilgen

Author Affiliations

1: Department of Dermatology, Christian-Albrechts-University, Kiel.

Articles cited by this

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet (1998) 3.84

Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol (1997) 2.32

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1998) 1.94

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol (1998) 1.82

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet (1990) 1.80

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol (1999) 1.78

A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer (1995) 1.52

Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother (1990) 1.37

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol (1998) 1.32

Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer (1984) 1.30

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol (1997) 1.20

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol (1991) 1.07

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol (1999) 1.01

Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a. Br J Cancer (1998) 0.83

The use of interferon-alpha in the treatment of cutaneous melanoma: a review. Melanoma Res (1998) 0.81

Long-term outcome of treatment with dacarbazine, cisplatin, interferon-alpha and intravenous high dose interleukin-2 in poor risk melanoma patients. Melanoma Res (1998) 0.81

Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma). Melanoma Res (1999) 0.79

Chemoimmunotherapy of melanoma. Is it time for phase III trials? Cancer (1995) 0.79

In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2. Nat Immun (1992) 0.78

Outpatient combination chemoimmunotherapy for patients with metastatic melanoma. Results of a phase I/II trial. Cancer (1999) 0.78

Articles by these authors

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48

Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med (1999) 6.04

Monoclonal antibodies show that neurofibrillary tangles and neurofilaments share antigenic determinants. Nature (1982) 4.93

The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27

Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J (1989) 4.04

Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol (2004) 3.97

Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med (1999) 3.37

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer (1998) 3.03

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood (1999) 2.98

Aberrant neurofilament phosphorylation in Alzheimer disease. Proc Natl Acad Sci U S A (1985) 2.96

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol (2006) 2.88

Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol (2001) 2.58

Introduction of intersubunit disulfide bonds in the membrane-distal region of the influenza hemagglutinin abolishes membrane fusion activity. Cell (1992) 2.47

Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat Immunol (2001) 2.29

[Skin cancer screening in Germany : The situation in 2014 with suggestions for the future]. Hautarzt (2015) 2.29

Human melanoma progression in skin reconstructs : biological significance of bFGF. Am J Pathol (2000) 2.23

Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant (2010) 2.10

Differences in efficacy between intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: clinical and pharmacoeconomic implications. Br J Dermatol (2001) 2.05

Using survey data to estimate prescription drug costs. Health Aff (Millwood) (1990) 2.00

Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. Br J Dermatol (1999) 1.96

The ABCD rule of dermatoscopy. High prospective value in the diagnosis of doubtful melanocytic skin lesions. J Am Acad Dermatol (1994) 1.94

"False-positive" anti-neutrophil cytoplasmic antibodies in HIV infection. Lancet (1990) 1.94

Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer (2009) 1.93

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol (2000) 1.92

Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. J Pathol (2006) 1.92

Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol (2000) 1.91

Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer (1998) 1.89

Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol (2007) 1.86

Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ (2006) 1.83

Awareness and early detection of cutaneous melanoma: an analysis of factors related to delay in treatment. Br J Dermatol (1999) 1.79

Successful and safe use of 2 min cold atmospheric argon plasma in chronic wounds: results of a randomized controlled trial. Br J Dermatol (2012) 1.78

Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia (2006) 1.77

Alzheimer changes in nondemented patients younger than sixty-five: possible early stages of Alzheimer's disease and senile dementia of Alzheimer type. Ann Neurol (1985) 1.75

Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol (2003) 1.75

Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood (2001) 1.74

A special type of senile plaque, possibly an initial stage. Acta Neuropathol (1987) 1.73

Some photochemical properties of chloroplast preparations from the chrysomonad Hymenomonas sp. Biochim Biophys Acta (1966) 1.72

Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol (2002) 1.71

Problems in defining cutoff points of continuous prognostic factors: example of tumor thickness in primary cutaneous melanoma. J Clin Epidemiol (1997) 1.69

Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol (1991) 1.68

Understanding the cost of a catastrophic drug benefit. Health Aff (Millwood) (1990) 1.66

The dermatoscopic pattern of clear-cell acanthoma resembles psoriasis vulgaris. Dermatology (2001) 1.66

Increase of melanocytic nevus counts in children during 5 years of follow-up and analysis of associated factors. Arch Dermatol (1996) 1.65

Subanesthetic dose of ketamine decreases prefrontal theta cordance in healthy volunteers: implications for antidepressant effect. Psychol Med (2009) 1.60

Neuritic plaques in senile dementia of Alzheimer type: a Golgi analysis in the hippocampal region. Brain Res (1983) 1.60

A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N Engl J Med (1991) 1.59

Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer (1997) 1.59

Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription-polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness. Br J Dermatol (2001) 1.56

Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost (2010) 1.56

[Psoriatic onycho-pachydermo- periostitis]. Z Rheumatol (2002) 1.56

Human papillomaviruses are commonly found in normal skin of immunocompetent hosts. J Invest Dermatol (1998) 1.54

Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res (2001) 1.53

Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer (2002) 1.51

Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer (1997) 1.50

Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem (2001) 1.50

Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol (2001) 1.49

Phenotypic and genotypic characteristics of a cell line from a squamous cell carcinoma of human skin. J Natl Cancer Inst (1982) 1.49

Dermoscopic classification of atypical melanocytic nevi (Clark nevi). Arch Dermatol (2001) 1.49

Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol (2007) 1.49

[Mechanical response of the frog and mammalian myocardium to changes in the action potential duration by constant current pulses]. Pflugers Arch (1969) 1.48

Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol (2007) 1.47

Epidemiologic evidence for the role of melanocytic nevi as risk markers and direct precursors of cutaneous malignant melanoma. Results of a case control study in melanoma patients and nonmelanoma control subjects. J Am Acad Dermatol (1992) 1.47

Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). Br J Dermatol (2012) 1.46

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46

Signaling of mechanical stretch in human keratinocytes via MAP kinases. J Invest Dermatol (2000) 1.46

Basal cell carcinomas in a tertiary referral centre: a systematic analysis. Br J Dermatol (2014) 1.46

A first prospective randomized controlled trial to decrease bacterial load using cold atmospheric argon plasma on chronic wounds in patients. Br J Dermatol (2010) 1.45

Basal-cell adhesion molecule (B-CAM) is induced in epithelial skin tumors and inflammatory epidermis, and is expressed at cell-cell and cell-substrate contact sites. J Invest Dermatol (2000) 1.44

Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma. Onkologie (2004) 1.43

Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol (2006) 1.43

Preservation of morphological, functional, and karyotypic traits during long-term culture and in vivo passage of two human skin squamous cell carcinomas. Cancer Res (1983) 1.42

A molecular mechanism for the induction of neurofilament bundling by aluminum ions. J Neurochem (1992) 1.42

Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res (1997) 1.42

PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res (2001) 1.42

Adverse reactions to local anesthetics: analysis of 197 cases. J Allergy Clin Immunol (1996) 1.41

In situ localization of IgG in epidermolysis bullosa acquisita by immunogold technique. J Am Acad Dermatol (1992) 1.40

Blood lead concentration and children's anthropometric dimensions in the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. J Pediatr (1999) 1.40

In melanoma, beta-catenin is a suppressor of invasion. Oncogene (2011) 1.40

[Botulinophilia. The new life style venenophilia]. Hautarzt (2001) 1.40

Age-related white matter atrophy in the human brain. Ann N Y Acad Sci (1992) 1.39

[Elective lymph node dissection in primary malignant melanoma]. Hautarzt (1996) 1.39

The transformation of pityriasis lichenoides chronica into parakeratosis variegata in an 11-year-old girl. Br J Dermatol (1997) 1.39

Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol (2004) 1.39

Oral hairy leukoplakia in 71 HIV-seropositive patients: clinical symptoms, relation to immunologic status, and prognostic significance. J Am Acad Dermatol (1996) 1.38

[The UV record. Document for quality control, therapy planning and risk assessment in dermatologic photo- and photochemotherapy]. Hautarzt (2000) 1.38

[Merkel cell tumor of the skin]. Dtsch Med Wochenschr (1997) 1.38

Senile dementia of Alzheimer type: astroglial reaction to extracellular neurofibrillary tangles in the hippocampus. An immunocytochemical and electron-microscopic study. Acta Neuropathol (1982) 1.38

Management of nevus spilus. Pediatr Dermatol (1999) 1.38

Energy and the u.s. Economy: a biophysical perspective. Science (1984) 1.37

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol (2000) 1.37

Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer (2010) 1.37

The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther (1998) 1.36

Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (2005) 1.36

Growth and differentiation characteristics of transformed keratinocytes from mouse and human skin in vitro and in vivo. J Invest Dermatol (1983) 1.36